Search news

Transform your market access in Asia-Pacific: a free virtual event

PRMA Healthcheck® for assets …

How will Covid-19 shape the evidence …

PRMA Healthcheck® for assets …

Why understanding payer archetypes is key …

Digital transformation in market access: don’…

Completing the puzzle: market access in …

Preparing for ICER assessments: key recommendations …

The evolution of the PRMA Healthcheck<...

Why on-demand insight is key to …

ICER 2020 value assessment framework: 7 updates that …

Digital transformation: shaping the future of …

How collaboration and connectivity can accelerate …

Navigating the updated 2020 ICER value assessment …

Breaking boundaries in market access: PRMA …

WEConnect: Connecting Women’s Enterprises with …

Payer and HTA submissions: how digital …

Reducing market access risk: how digital …

The Covid-19 pandemic could mark the …

Wherever we work, we work together

Home working: 6 tips for fostering team …

COVID-19: how your market access can …

Wellbeing at PRMA Consulting

Payer insight: 5 ways to get the …

Up to 30% of global HTA template …

Emerging biomarker in a hemato-oncology indication

FDA unveils guidance for Covid-19 trials.

Big Pharma companies join forces for …

Understanding the impact of the ESMO …

PRMA Consulting expands its US presence

Market access roadmap in hemophilia B

The top 10 drugs by sales increase …

China on the cusp of anticancer …

Driving market access success in the …

How a leading pharma company gained …

Proactively managing HTA challenges for follow-on …

Healthcheck assessment for novel asset in …

How to drive payer submission readiness …

What is the best system to …

10 FDA specifics on how sponsors should …

Digitization in primary research: a smart …

A path forward for CAR-T therapy …

The things you need to know …

Are you in touch with the …

Transforming value and access outcomes in …

Accelerate the time to patient access …

The influence of the patient voice …

HEOR in the ear of Covid-19: …

How to identify the potential for …

Managed entry agreements: learnings for successful …

Managed entry agreements: theory and principals

Are you in touch with the …

Applying Machine Learning to Healthcare Outcomes …

Panel discusses creative financing proposals

NICE numbers at 20

This top-5 pharma company chose the …

Selectively targeting cancerous T-Cells using CAR-T …

Take part in our consultation and …

Pharma, late to digital game, rushes …

Payer insight: 5 ways to get the …

How modernization is effecting the FDA

In a small study, a cancer …

Finalist in the HealthEconomics.com’s 1…

The Fierce Innovation Award identifying outstanding …

EUnetHTA joint clinical assessments: where have …

ISPOR launches expanded HEOR Presentations Database

Spanish authorities back plans to promote …

MHRA: the potential impact of COVID-19 …

Estimating the eligible patient population for …

61st ASH Annual Meeting and Exposition

Digital innovation empowers global teams and …

Toby Gosden joins PRMA Consulting

Nathan White joins PRMA Consulting

Future proofing for the 2020s market …

Mapping patient involvement in NICE appraisals …

Watch and vote in the 2019 Health …

New drugs: where did we go …

Pairing targeted drugs could overcome breast, …

A Review of Immune-Mediated Adverse Events …

Keen to stay out front in …

Do market access withdrawals impact patient …

Implications of “no deal” Brexit for …

Willingness to pay for quality-adjusted life …

Prices Are Not “Reimbursements”.

Orphan drug re-assessments in Germany: the …

Development of a value story, GVD, …

Developing an economic model to optimize …

Do your global value dossiers contain …

How digital technology is transforming market …

ISPOR Europe 2019

Managed entry agreements: lessons from EU5

Personalised reimbursement: a risk-sharing model for …

Improving affordability of new essential cancer …

Swiss to take on big pharma …

CAR T-Cell therapy: a microcosm for …

Lani Alison on how innovation is …

Car-T: the first agreement for new …

A watchdog group sets aside emotions …

Here come the oncology biosimilars in …

How will digital technology transform every …

Developing an international market access strategy …

Critically evaluating pricing and access risks …

Free eBook: how to accelerate the …

Overcoming the market access challenges associated …

CAR-T therapy: the future begins to …

FDA Unveils Pilot Program to Expand …

EUnetHTA: Practical considerations when critically assessing …

Data collection infrastructure for patient outcomes …

The rise of patient engagement

CMS proposed rule requires hospitals to …

ARM Q2 2019 Regenerative Medicine Sector Report

Will long-term post-marketing studies become the …

ICER methods could be illegal in …

FDA and FTC announce new efforts …

Drug Quality: FDA officials discuss perceptions.

Championing digital transformation within biotech and …

Maximize the pricing and market access …

Developing a market access and HEOR …

Pricing and reimbursement in Canada: a …

Exploring the challenges for pricing and …

Cell therapy weekly: Taiwan expands availability …

Potential solutions for pricing and reimbursement …

NICE reviews number crunching methods as …

Number of manufacturers and generic drug …

Travis Broome discusses participating in multiple …

Indication-specific pricing: the obvious solution

Why Japan’s new cost-effectiveness assessment …

As patents expire are oncology biosimilars …

ICER expands assessment timelines up to 3 …

Creating compelling real-world evidence that supports …

The relevance of patient perspectives to …

Dual CAR-T cell therapy shows potential …

Disinvestment activities and candidates in the …

Top 10 biotech bay companies by revenue

Payer perspectives on cell and gene …

Improving pharmaceutical portfolio management and decision-making …

Evidence synthesis and development of economic …

Combinations: P&R considerations

Incorporating the patient voice in market …

Pricing and reimbursement of CAR‐T …

Improve health technology assessment submissions

Demonstrating value using a new approach …

Managed entry agreements: regional and national …

A comparison of EMA and FDA …

Cystic fibrosis drugs rejected for use …

The US Military Health System: promoting …

How development of gene therapies impact …

Biosimilars make progress in the Canadian …

Market access considerations for CAR-Ts: insights …

Blocking competitor intrusion in competitive pharmaceutical …

Measuring survival benefit in oncology health …

Top-5 pharma discovers a new way …

Exploring the benefits of cloud computing …

Protecting your market access data. 10 questions …

Identifying critical risks for payer decision-making

Artificial intelligence could globally revolutionize health …

Validation of the European Organisation for …

A framework for aiding the translation …

2019’s fiercest women in life sciences

FDA approves first therapy to treat …

Protect your market access data: the …

Four recommendations to kick-start the digital …

Patient-centricity: shaping value generation for HTA …

Anticipate evidence needs early on and …

Exploring the challenges for pricing and …

Assessing evidence generation strategies for an …

Funding academic innovations in advanced therapies

Achieving a positive HTA outcome with …

Managed entry agreements: regional and national …

Five strategies for CAR-T pricing and …

Bolstering payer discussions to solve persistent …

Review of CAR-T assessments and implications …

NICE recommends funding for psoriasis and …

State-of-the-art for CAR T-cell therapy for …

Pharma & patient organisation collaborations could improve …

Price increases of protected-class drugs in …

Use of real-world data sources for …

The fragility of phase 3 trials supporting …

Emerging markets are ‘blue oceans’ for …

EMA promotes a robust methodology for …

Recommendations for successfully developing managed entry …

Market access for PD-1 inhibitors: where …

Strategic roadmap for optimized global market …

Designing effective managed entry agreements: insight …

Patient-centricity: a crucial approach for market …

Paper proposes methodology to “Protect Health …

Price transparency rule could pose challenges

Overcoming current barriers to the use …

A new targeted gene therapy shows …

Does 1+1 always equal 2? Valuing combinations

Accelerating decision-making for international market access

Landscape assessments and market access strategy …

Biosimilars: market access considerations

Is time running out for value …

CMS finalizes long-sought rules for Medicare …

Pursuit of tumor-infiltrating lymphocyte immunotherapy speeds …

4 ways to adapt to new oncology …

Strategic projects to inform commercialization decisions …

Strategic and tactical support achieves HTA …

Exploring the challenges for pricing and …

Clarity or confusion: the role of …

Transforming the market access landscape: the …

Recommendations for an ophthalmology launch plan …

CHMP issues positive opinion for 13 medicines

Some cancer patients are choosing experimental …

Do no financial harm: how to …

Drug prices: shortages remain problem

Using payer perspectives to inform evidence …

Evaluate how digital technology can better …

Digitally transforming health technology assessment (HTA) …

New Committee Brings Diverse Patient, Family, …

PRMA Consulting Expert Advisory Group on …

Using AI to predict the outcome …

Achieving a variable price by indication: …

Pharma continues to get poor grades …

Indication-based pricing: your free eBook download

Social Media Offers Unexpected Benefits for …

The fragility of phase 3 trials supporting …

Lessons From Mercosur Multi-Country Pricing Negotiations

What is market access?

A New Method to Determine the …

Value frameworks scoring of a new …

As price pressure mounts, pharma companies …

Biosimilar drug market emerging trends, size, …

Non-binding guidance: real-world evidence in drug …

Load more

Please contact us for more information